Document Detail


Effects of 12 weeks of tadalafil treatment on ejaculatory and orgasmic dysfunction and sexual satisfaction in patients with mild to severe erectile dysfunction: integrated analysis of 17 placebo-controlled studies.
MedLine Citation:
PMID:  23356749     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
OBJECTIVES: To compare effects of tadalafil on ejaculatory and orgasmic function in patients presenting with erectile dysfunction (ED). To determine the effects of post-treatment ejaculatory dysfunction (EjD) and orgasmic dysfunction (OD) on measures of sexual satisfaction.
PATIENTS AND METHODS: Data from 17 placebo-controlled 12-week trials of tadalafil (5, 10, 20 mg) as needed in patients with ED were integrated. EjD and OD severities were defined by patient responses to the International Index of Erectile Function, question 9 (IIEF-Q9; ejaculation) and IIEF-Q10 (orgasm), respectively. Satisfaction was evaluated using the intercourse and overall satisfaction domains of the IIEF and Sexual Encounter Profile question 5. Analyses of covariance were performed to compare mean ejaculatory function and orgasmic function, and chi-squared tests evaluated differences in endpoint responses to IIEF-Q9 and IIEF-Q10.
RESULTS: A total of 3581 randomized subjects were studied. Treatment with tadalafil 10 or 20 mg was associated with significant increases in ejaculatory and orgasmic function (vs placebo) across all baseline ED, EjD, and OD severity strata. In the tadalafil group, 66% of subjects with severe EjD reported improved ejaculatory function compared with 36% in the placebo group (P < 0.001). Similarly, 66% of the tadalafil-treated subjects (vs 35% for placebo; P < 0.001) with severe OD reported improvement. Residual severe EjD and OD after treatment had negative impacts on sexual satisfaction. Limitations of the analysis include its retrospective nature and the use of an instrument (IIEF) with as yet unknown performance in measuring treatment responses for EjD and OD.
CONCLUSIONS: Tadalafil treatment was associated with significant improvements in ejaculatory function, orgasmic function and sexual satisfaction. Proportions of subjects reporting improved ejaculatory or orgasmic function were ≈ twofold higher with tadalafil than with placebo. These findings warrant corroboration in prospective trials of patients with EjD or OD (without ED).
Authors:
Darius A Paduch; Alexander Bolyakov; Paula K Polzer; Steven D Watts
Related Documents :
9552069 - Comorbidity and functional status are independent in older cancer patients.
24849309 - Subthalamic stimulation improves motor function but not home and neighborhood mobility.
2741999 - Internal and external validity in two studies that compared treatment methods.
19912069 - Validation of the bowel function index to detect clinically meaningful changes in opioi...
11686759 - The psychometric properties of the chinese dialysis quality of life scale for hong kong...
24062399 - Functional decline in older patients with cancer receiving first-line chemotherapy.
2348339 - The depressive experiences questionnaire: validity and psychological correlates in a cl...
19819909 - Use of benznidazole to treat chronic chagas' disease: a systematic review with a meta-a...
23983989 - Effect of epigallocatechin gallate supplementation in schizophrenia and bipolar disorde...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  BJU international     Volume:  111     ISSN:  1464-410X     ISO Abbreviation:  BJU Int.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100886721     Medline TA:  BJU Int     Country:  England    
Other Details:
Languages:  eng     Pagination:  334-43     Citation Subset:  IM    
Copyright Information:
© 2013 BJU International.
Affiliation:
Department of Urology and Reproductive Medicine, Weill Cornell Medical College, New York, NY; Consulting Research Services, Inc., Red Bank, NJ.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplas...
Next Document:  Upper gastrointestinal bleeding: incidence, etiology and outcomes in a population-based setting.